title: Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: a 12-month, placebo-controlled study.
abstract: To evaluate the action of vildagliptin + metformin on some adipocytokine levels, glycemic control, and β-cell function in type 2 diabetic patients.
  
  
  
  A total of 171 patients with poor glycemic control were instructed to add after a 8 ± 2 month-run-in period with metformin, vildagliptin 50 mg twice a day or placebo for 12 months.
  
  
  
  We evaluated at 3, 6, 9, and 12 months, the body mass index (BMI), glycemic control, fasting plasma insulin (FPI), homeostasis model assessment insulin resistance index (HOMA-IR), homeostasis model assessment β-cell function index (HOMA-β), fasting plasma proinsulin (FPr), proinsulin/fasting plasma insulin ratio (Pr/FPI ratio), C-peptide, glucagon, resistin, retinol-binding protein-4 (RBP-4), chemerin, and tumor necrosis factor-α (TNF-α). Patients also underwent a combined euglycemic hyperinsulinemic and hyperglycemic clamp, with subsequent arginine stimulation to assess insulin sensitivity and insulin secretion.
  
  
  
  After 12 months of vildagliptin + metformin, we observed a better decrease of body weight, glycemic control, HOMA-IR, and glucagon, and a better increase of HOMA-β, and of all the measures of β-cell function, compared to placebo + metformin. Vildagliptin + metformin also decreased resistin, RBP-4, and chemerin better.
  
  
  
  Vildagliptin seems to have a positive action on some adipocytokines related to inflammation.
authors.affiliation: University of Pavia, Department of Internal Medicine and Therapeutics, Fondazione IRCCS Policlinico, S. Matteo, PAVIA, P.le C. Golgi, 2 - 27100 Pavia, Italy. giuseppe.derosa@unipv.it
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Derosa
authors.forename: Pietro D
authors.initials: PD
authors.lastname: Ragonesi
authors.forename: Anna
authors.initials: A
authors.lastname: Carbone
authors.forename: Elena
authors.initials: E
authors.lastname: Fogari
authors.forename: Angela
authors.initials: A
authors.lastname: D'Angelo
authors.forename: Arrigo F G
authors.initials: AF
authors.lastname: Cicero
authors.forename: Pamela
authors.initials: P
authors.lastname: Maffioli
mesh_terms: D000218:Adamantane / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000328:Adult; D018925:Chemokines / Q000097:blood*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism / Q000503:physiopathology; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use*; D004311:Double-Blind Method; D015536:Down-Regulation / Q000187:drug effects*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006943:Hyperglycemia / Q000517:prevention & control; D007328:Insulin / Q000378:metabolism; D007333:Insulin Resistance; D000078790:Insulin Secretion; D050417:Insulin-Secreting Cells / Q000187:drug effects / Q000378:metabolism; D057194:Intention to Treat Analysis; D036341:Intercellular Signaling Peptides and Proteins; D008297:Male; D008687:Metformin / Q000627:therapeutic use; D008875:Middle Aged; D009570:Nitriles / Q000627:therapeutic use*; D011759:Pyrrolidines / Q000627:therapeutic use*; D052243:Resistin / Q000097:blood*; D054839:Retinol-Binding Proteins, Plasma / Q000032:analysis*; D000077597:Vildagliptin
chemical_list: D018925:Chemokines; D054873:Dipeptidyl-Peptidase IV Inhibitors; D007328:Insulin; D036341:Intercellular Signaling Peptides and Proteins; D009570:Nitriles; D011759:Pyrrolidines; C478630:RARRES2 protein, human; C101326:RBP4 protein, human; C499624:RETN protein, human; D052243:Resistin; D054839:Retinol-Binding Proteins, Plasma; D008687:Metformin; D000077597:Vildagliptin; D000218:Adamantane